HUP0001316A2 - Eljárás rosszindulatú emberi daganatok kimutatására és lokalizálására - Google Patents
Eljárás rosszindulatú emberi daganatok kimutatására és lokalizálásáraInfo
- Publication number
- HUP0001316A2 HUP0001316A2 HU0001316A HUP0001316A HUP0001316A2 HU P0001316 A2 HUP0001316 A2 HU P0001316A2 HU 0001316 A HU0001316 A HU 0001316A HU P0001316 A HUP0001316 A HU P0001316A HU P0001316 A2 HUP0001316 A2 HU P0001316A2
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical preparation
- subject
- localization
- tumors
- receptor agonist
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 230000004807 localization Effects 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 3
- 101800001814 Neurotensin Proteins 0.000 abstract 2
- 102000050267 Neurotensin Human genes 0.000 abstract 2
- 238000003384 imaging method Methods 0.000 abstract 2
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000002285 radioactive effect Effects 0.000 abstract 2
- 239000000018 receptor agonist Substances 0.000 abstract 2
- 229940044601 receptor agonist Drugs 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 102000017922 Neurotensin receptor Human genes 0.000 abstract 1
- 108060003370 Neurotensin receptor Proteins 0.000 abstract 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 229910000831 Steel Inorganic materials 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000003748 differential diagnosis Methods 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 abstract 1
- 239000010959 steel Substances 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/085—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being neurotensin
Abstract
A találmány tárgya eljárás emberi szervezetben történő rősszindűlatúdaganatők vagy szöveti áttéteik kiműtatására és lőkalizálására azőnszövetekben, amelyek egészséges vagy nem-neőplasztikűs krónikűsgyűlladásős állapőtban lényeges mennyiségű neűrőtenzin-receptőrtólmentesek, ahől (i) a fenti szervezetbe egy készítmény jűttatnak, amelykülső leképezésre megfelelő mennyiségű radiőaktív jelzett peptidettartalmaz - amely neűrőtenzin (NT), NT-receptőr agőnista, NT-receptőrantagőnista, NT-analóg vagy NT-származék lehet -, majd (ii) a testbenlévő célterületek kiműtatatására a fenti szervezetet radiőaktívscanning vagy mágneses rezőnanciás leképezés űtján külső képalkőtóeljárásnak vetik alá. A találmány tővábbi tárgya eljárás az előbbidaganatők terápiás kezelésére, ahől a szervezetbe jűttatnak erre acélra megfelelően jelzett fenti peptidet tővábbá a hasnyálmirigybizőnyős tűmőr rákjainak differenciáldiagnózisára (nevezetesen azexőkrin hasnyálmirigy-vezeték-ráknak). A találmány tárgya még kiműtatásra használható gyógyszerkészítmény,terápiás kezelésre alkalmazható gyógyszerkészítmény és radiőaktívgyógyszerkészítmény előállítására alkalmas kit. ŕ
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97200297 | 1997-02-03 | ||
| PCT/US1998/001964 WO1998033531A1 (en) | 1997-02-03 | 1998-02-02 | Method for the detection and localization of malignant human tumours |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0001316A2 true HUP0001316A2 (hu) | 2000-09-28 |
| HUP0001316A3 HUP0001316A3 (en) | 2001-10-29 |
Family
ID=26146106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001316A HUP0001316A3 (en) | 1997-02-03 | 1998-02-02 | Method for the detection and localization of malignant human tumours |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6312661B1 (hu) |
| EP (1) | EP0968001B1 (hu) |
| JP (1) | JP2001511152A (hu) |
| AT (1) | ATE253381T1 (hu) |
| AU (1) | AU728712C (hu) |
| CA (1) | CA2279530C (hu) |
| DE (1) | DE69819478T2 (hu) |
| HU (1) | HUP0001316A3 (hu) |
| IL (1) | IL131386A0 (hu) |
| NO (1) | NO993846L (hu) |
| WO (1) | WO1998033531A1 (hu) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3340699B2 (ja) * | 1998-06-05 | 2002-11-05 | 東京瓦斯株式会社 | 膵外分泌機能診断剤 |
| US7232559B1 (en) | 1999-06-04 | 2007-06-19 | Tokyo Gas Company Limited | Diagnostic agents for pancreatic exocrine function |
| WO2001030398A2 (en) * | 1999-10-22 | 2001-05-03 | Insight Neuroimaging Systems, Llc | Ligand chelated paramagnetic mri contrast agents |
| US7630907B2 (en) * | 2001-10-30 | 2009-12-08 | Biodose, Llc | Algorithm and program for the handling and administration of radioactive pharmaceuticals |
| US8175890B2 (en) * | 2001-10-30 | 2012-05-08 | Biodose, Llc | Pharmacy based method and algorithm for handling of radioactive pharmaceuticals and generating of reports therefrom |
| US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| US20040039241A1 (en) * | 2002-05-29 | 2004-02-26 | Biodose Llc | Integrated distribution and communication process and algorithm for providing, handling, distributing or generating reports regarding radioactive pharmaceuticals |
| AU2003259172A1 (en) * | 2002-07-24 | 2004-02-09 | The Salk Institute For Biological Studies | Receptor (sstr4)- selective somatostatin analogs |
| GR1004637B (el) * | 2003-04-04 | 2004-07-23 | Βιομεντικααλαιφασαιενσισαανωνυμηαεταιριααφαρμακευτικωναπροιοντωναα | Συνθεσηαβιολογικηακαιαπροκλινικηααξιολογησηααναλογωνανευροτενσινησα}@@bατροποποιημενωναμεαπαραγωγαατουα@ϊ@τετρααζαενδεκανιουα}@ϊ@tetraazaundecanebακαιαεπισημασμενωναμεατεχνητιο@mα}αηαλλααραδιονουκλιδιαατουατεχνητιουbαη@καιαρηνιο@ϊϊα}΄ηααλλααραδιονουκλιδιαατουαρηνιουbαγιααεφαρμογηαστηναογκολογιαα |
| EP2474328A3 (en) * | 2003-09-17 | 2012-07-18 | Board Of Regents, The University Of Texas System | Mechanism-based targeted pancreatic beta cell imaging and therapy |
| US7507547B2 (en) * | 2004-09-09 | 2009-03-24 | University Of Massachusetts | Screening assays for antioxidants and antiproliferative compounds |
| US20060062729A1 (en) * | 2004-09-09 | 2006-03-23 | Carraway Robert E | Enhanced ligand binding to neurotensin receptors |
| ES2538002T3 (es) | 2009-01-07 | 2015-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama |
| EP2454272B1 (en) * | 2009-07-16 | 2017-08-23 | IASON GmbH | Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors |
| US8378134B2 (en) | 2009-09-30 | 2013-02-19 | General Electric Company | Hydroxylated contrast enhancement agents |
| EP2740726A1 (en) | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| EP2954933A1 (en) | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| EP2954934A1 (en) | 2014-06-11 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand and use thereof |
| JP7065567B2 (ja) | 2014-06-10 | 2022-05-12 | スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ニューロテンシン受容体リガンドを含むコンジュゲートおよびそれらの使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2687680A1 (fr) * | 1992-02-20 | 1993-08-27 | Centre Nat Rech Scient | Procede de marquage de proteines et de peptides par acylation de leur fonction alpha aminee par un reactif comportant une fonction carboxylique activee. |
| AU3967593A (en) * | 1992-03-25 | 1993-10-21 | Mallinckrodt Medical, Inc. | Method of intraoperatively detecting and locating tumoral tissues |
| CA2086453A1 (en) * | 1992-12-30 | 1994-07-01 | Mcgill University | Marker for neurotensin receptor |
| DE4337599A1 (de) * | 1993-11-01 | 1995-05-04 | Diagnostikforschung Inst | Metallbindende cysteinfreie Peptide für Diagnose und Therapie, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| JPH11514329A (ja) * | 1994-02-18 | 1999-12-07 | マリンクロット・メディカル・インコーポレイテッド | 標識化ペプチド化合物 |
| FR2720066B1 (fr) * | 1994-05-20 | 1996-06-28 | Rhone Poulenc Rorer Sa | Peptides antagonistes de la neurotensine. |
| FR2722193B1 (fr) * | 1994-07-08 | 1996-10-04 | Sanofi Sa | Derives n-oxydes de 1-(7-chloro-4-quinoleinyl)pyrazole-3-carboxamides substitues, procede pour leur preparation et les compositions pharmaceitiques les contenant |
| WO1996023527A1 (en) * | 1995-02-03 | 1996-08-08 | Mallinckrodt Medical, Inc. | Method for the detection and localization of malignant human tumours |
-
1998
- 1998-02-02 EP EP98904839A patent/EP0968001B1/en not_active Expired - Lifetime
- 1998-02-02 JP JP53317698A patent/JP2001511152A/ja active Pending
- 1998-02-02 WO PCT/US1998/001964 patent/WO1998033531A1/en not_active Application Discontinuation
- 1998-02-02 AU AU62622/98A patent/AU728712C/en not_active Ceased
- 1998-02-02 CA CA002279530A patent/CA2279530C/en not_active Expired - Lifetime
- 1998-02-02 US US09/355,869 patent/US6312661B1/en not_active Expired - Lifetime
- 1998-02-02 IL IL13138698A patent/IL131386A0/xx unknown
- 1998-02-02 HU HU0001316A patent/HUP0001316A3/hu unknown
- 1998-02-02 AT AT98904839T patent/ATE253381T1/de not_active IP Right Cessation
- 1998-02-02 DE DE69819478T patent/DE69819478T2/de not_active Expired - Lifetime
-
1999
- 1999-08-10 NO NO993846A patent/NO993846L/no not_active Application Discontinuation
-
2001
- 2001-11-05 US US09/985,672 patent/US20020155064A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69819478T2 (de) | 2004-09-02 |
| EP0968001A1 (en) | 2000-01-05 |
| US20020155064A1 (en) | 2002-10-24 |
| US6312661B1 (en) | 2001-11-06 |
| HUP0001316A3 (en) | 2001-10-29 |
| EP0968001B1 (en) | 2003-11-05 |
| JP2001511152A (ja) | 2001-08-07 |
| NO993846L (no) | 1999-09-09 |
| NO993846D0 (no) | 1999-08-10 |
| AU728712B2 (en) | 2001-01-18 |
| CA2279530C (en) | 2009-04-28 |
| DE69819478D1 (de) | 2003-12-11 |
| CA2279530A1 (en) | 1998-08-06 |
| AU6262298A (en) | 1998-08-25 |
| AU728712C (en) | 2001-07-19 |
| IL131386A0 (en) | 2001-01-28 |
| ATE253381T1 (de) | 2003-11-15 |
| WO1998033531A1 (en) | 1998-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0001316A2 (hu) | Eljárás rosszindulatú emberi daganatok kimutatására és lokalizálására | |
| TR200103560T2 (tr) | Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı | |
| PT1349870E (pt) | Composições para a terapêutica e diagnóstico do cancro do ovário | |
| NZ330887A (en) | Monoclonals and polyclonals antibodies for the diagnosis of breast cancer | |
| Giovannini et al. | Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer | |
| HUP0401903A2 (hu) | Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére | |
| Panagiotidis et al. | Rib fractures mimicking bone metastases in 18F-PSMA-1007 PET/CT for prostate cancer | |
| Mantripragada et al. | Response to anti-PD-1 therapy in metastatic Merkel cell carcinoma metastatic to the heart and pancreas | |
| Tripathi et al. | VPAC1 targeted 64Cu-TP3805 positron emission tomography imaging of prostate cancer: Preliminary evaluation in man | |
| EP1706145A4 (en) | AUTOANTIC BODY USED IN TUMOR IMAGING AND CANCER TREATMENT AS A CARRIER FOR PHARMACEUTICAL COMPOUNDS | |
| Liu et al. | RGD-functionalised melanin nanoparticles for intraoperative photoacoustic imaging-guided breast cancer surgery | |
| Eiber et al. | 18F-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy | |
| DE69942031D1 (de) | In prostatakrebs exprimiertes gen | |
| Lilleby et al. | Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation | |
| Kirsch | Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador® M) | |
| Scatozza et al. | Melanogenesis and autophagy in melanoma | |
| Bonadies et al. | Electrochemotherapy of a multirecurrent dermatofibrosarcoma protuberans of the orbital margin: a case report | |
| RU2712009C1 (ru) | Способ лучевой терапии больных с локорегионарными рецидивами рака предстательной железы после радикальной простатэктомии и наличием единичных отдаленных метастазов | |
| JP2002516882A5 (hu) | ||
| HUP0300007A2 (en) | Antibody with specificity for colon cancer | |
| Lee et al. | Effect of angiogenesis induced by consecutive intramuscular injections of vascular endothelial growth factor in a hindlimb ischemic mouse model | |
| MX2021015467A (es) | Compuestos y metodos de uso. | |
| Khan et al. | Combined Immunotherapy in Metastatic Melanoma with Unknown Primary | |
| ATE355304T1 (de) | Radiomarkierte vip-analoge zur diagnose und therapie | |
| Carlini et al. | Adrenal glands metastases from malignant melanoma. Laparoscopic bilateral adrenalectomy |